Nitin Joshi

Researchers develop “smart” nanoparticles to deliver targeted gene therapy in osteoarthritis. Read more from @MassGenBrigham @NJoshiBWH and colleagues: massgeneralbrigham.org/en/about/newsr… @NatureNano

@MassGenBrigham @MGBResearchNews @harvardmed #NatureNanotechnology #GeneTherapy #mRNA #Nanomedicine #Osteoarthritis

Huge congratulations to @DewaniMahima and @jgao_umass for leading this work. Grateful to our collaborators Li Zeng, Anjali Mamidwar, @MrJeffKarp and the rest of the team who made this possible. Excited about what this means for precision gene therapies in degenerative diseases!

Our new paper is out in @NatureNano We describe a non-viral gene delivery platform that delivers mRNA precisely to damaged cartilage in osteoarthritis and self-regulates targeting and expression as disease severity increases. nature.com/articles/s4156… massgeneralbrigham.org/en/about/newsr…

@zongmin_zhao @NatureComms Congratulations Zongmin!

Happy to share our new work in ⁦@NatureComms⁩. We report ACT-DC, a nanoparticle-boosted dendritic cell therapy that turns tumor into an effective vaccination site for in situ immunization. nature.com/articles/s4146…

HUGE thanks to my collaborators @MrJeffKarp and Joerg Ermann, and congratulations to the entire team for the tremendous work over the years. Thank you @NIH @NIH_NIAMS @DeptofDefense @NFLPA @RheumResearch for the support. @MassGenBrigham @BrighamWomens @harvardmed @BrighamAnes

🔥Our latest work is out in PNAS! We report a mechanically resilient hydrogel that enables sustained, localized delivery of therapies for post-traumatic osteoarthritis, without breaking down under physical activities like running! pnas.org/doi/10.1073/pn… @PNASNews

Blood–brain-barrier-crossing lipid nanoparticles (BLNPs). Wonderful academia and industry collaborations @IcahnMountSinai @biogen @OhioState! Thanks @NIGMS & @NIDAnews! Thanks @NatureMaterials editor and reviewers!

Rising Stars 2025! @BrianAguado Haogang Cai @JunChenLab @DengYanxiang @mhhettiaratchi @LaurelHind Guosong Hong @priscilla_hwang @NJoshiBWH @IsaacLeeLab Jiahe Li @ClaudiaLoebel @mistrigr @KarinaNakayama @hadi_nia @LabRaghavan @DrRituRaman @telomerase2 @Yichun_Wang_Lab @jaweinst

@_SumanB Huge congratulations Suman!

Stoked our @MayoClinic team secured @ARPA_H funding to develop a bioelectronic cell therapy device for IBD! The #EASE platform will transform inflammatory disease management. Excited to work with an exceptional team of engineers, scientists, clinicians, and industry partners!

@TheKulkarniLab Thank you so much Ashish!!

@NJoshiBWH Interesting work! Huge Congrats to @NJoshiBWH and team 👏

Thrilled to share our new research in Advanced Materials, describing a Pathogen Capture and Neutralizing Spray (PCANS) with potential to provide extra protection against a broad range of respiratory infections when masks and vaccines fall short. onlinelibrary.wiley.com/doi/abs/10.100…

@sachinbhag Thanks so much Sachin!

@NJoshiBWH Congratulations @NJoshiBWH! Amazing work!!

Check out the press release describing our Pathogen Capture and Neutralizing Spray (PCANS) with potential to prevent a broad range of respiratory infections. @MrJeffKarp @harvardmed @BrighamWomens news.harvard.edu/gazette/story/… brighamandwomens.org/about-bwh/news…

@suman_pahal Thank you!

@pkvemula @NJoshiBWH @MrJeffKarp Congratulations @NJoshiBWH

@pkvemula Thank you so much Praveen!!

@NJoshiBWH Innovative work. Congratulations @NJoshiBWH @MrJeffKarp and team👏👏👏

@AnkitGangrade11 Thanks you Ankit!

@NJoshiBWH Congratulations Dr @NJoshiBWH. Very innovative 💡 👏

A NEW nasal spray that trap & neutralize not only SARS-CoV-2, Influenza, RSV, Adeno & many other viruses & bacteria that are inhaled into the nose, immobilizing them until they die. The substance is >99.9% effective & contains no drugs 1/

🔥 New, promising data on Profi Nasal Spray (aka PCANS) as prophylaxis for respiratory viruses: “The researchers developed the formulation and studied its ability to capture respiratory droplets in a 3D-printed replica of a human nose. They showed that when sprayed in the nasal cavity replica, PCANS captured twice as many droplets as mucus alone.  “PCANS forms a gel, increasing its mechanical strength by a hundred times, forming a solid barrier,” said primary author John Joseph, PhD, a former postdoctoral fellow at Brigham and Women’s Hospital. “It blocked and neutralized almost 100% of all viruses and bacteria we tested, including Influenza, SARS-CoV-2, RSV, adenovirus, K Pneumonia and more.” Experiments in mice showed that a single dose of the PCANS nasal spray could effectively block infection from an influenza virus (PR8) at 25 times the lethal dose. Virus levels in the lungs were reduced by >99.99%, and the inflammatory cells and cytokines in the lungs of PCANS-treated animals were normal.”

In a preclinical study, @NJoshiBWH, @MrJeffKarp and their collaborators have created and tested an innovative drug-free nasal spray that has the potential to be a public health tool in reducing respiratory diseases. buff.ly/3XXwDTm